OneScreen.ai Doubles Revenue Every Quarter, Triples Headcount in 2021
Out-of-home (OOH) advertising startup marks various milestones as it preps to expand on the first-of-its-kind…
News
Payoneer Study Finds Freelance Workers Benefited from Surge in Demand and Increased Pay Amidst Ongoing Pandemic
Payoneer’s 2022 Global Freelancer Income Report reveals that the worldwide average hourly freelance rate has…
J.D. Power Builds on EVs, Mobility, Connected Vehicles and Consulting with New Hires, Promotions
TROY, Mich.–(BUSINESS WIRE)–J.D. Power, a global leader in data analytics and consumer intelligence, today announced…
COPT Announces Tax Treatment of 2021 Distributions
COLUMBIA, Md.–(BUSINESS WIRE)–Corporate Office Properties Trust (“COPT” or the Company) (NYSE: OFC) announced the 2021…
MPC Alliance announces new Board of Directors
San Francisco, January 31, 2022 – MPC Alliance has started the year by appointing new…
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved…
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late…
XORTX Provides Corporate Update
Synopsis of 2021 Achievements and Key Activities for 2022 CALGARY, Alberta, Jan. 31, 2022 (GLOBE…
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company…
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022 GAITHERSBURG, Md.,…
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology…
Medicenna Announces Formation of its Scientific Advisory Board
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the…
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
– VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume…
Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the…
Akouos to Participate in Upcoming February Virtual Investor Conferences
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic…
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
LA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded…
Fennec Pharmaceuticals Announces Management Change
RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:…
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
New data support Phase 3 development of Nyxol alone as a durable single eye drop…
Wolfspeed Announces Offering of $500 Million of Convertible Senior Notes
DURHAM, N.C.–(BUSINESS WIRE)–Wolfspeed, Inc. (NYSE: WOLF) (“Wolfspeed”) today announced that it intends to offer, subject…
GoldSpot Discoveries Engaged by Western Exploration Inc. for the Aura Project in Nevada
Toronto, Ontario–(Newsfile Corp. – January 31, 2022) – GoldSpot Discoveries Corp. (TSXV: SPOT) (OTCQX: SPOFF)…